Arcus Biosciences Inc. (RCUS)
Arcus Biosciences Statistics
Share Statistics
Arcus Biosciences has 105.84M shares outstanding. The number of shares has increased by 0.71% in one year.
| Shares Outstanding | 105.84M |
| Shares Change (YoY) | 0.71% |
| Shares Change (QoQ) | 0.09% |
| Owned by Institutions (%) | 91.8% |
| Shares Floating | 64.9M |
| Failed to Deliver (FTD) Shares | 34 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 8.25M, so 9.01% of the outstanding shares have been sold short.
| Short Interest | 8.25M |
| Short % of Shares Out | 9.01% |
| Short % of Float | 16.74% |
| Short Ratio (days to cover) | 13.12 |
Valuation Ratios
The PE ratio is -4.74 and the forward PE ratio is -3.62. Arcus Biosciences's PEG ratio is 0.19.
| PE Ratio | -4.74 |
| Forward PE | -3.62 |
| PS Ratio | 5.2 |
| Forward PS | 1 |
| PB Ratio | 2.77 |
| P/FCF Ratio | -7.62 |
| PEG Ratio | 0.19 |
Enterprise Valuation
Arcus Biosciences Inc. has an Enterprise Value (EV) of 1.3B.
| EV / Earnings | -4.58 |
| EV / Sales | 5.03 |
| EV / EBITDA | -4.82 |
| EV / EBIT | -3.93 |
| EV / FCF | -7.37 |
Financial Position
The company has a current ratio of 4.5, with a Debt / Equity ratio of 0.1.
| Current Ratio | 4.5 |
| Quick Ratio | 4.5 |
| Debt / Equity | 0.1 |
| Total Debt / Capitalization | 9.01 |
| Cash Flow / Debt | -3.54 |
| Interest Coverage | -82.5 |
Financial Efficiency
Return on equity (ROE) is -0.58% and return on capital (ROIC) is -62.13%.
| Return on Equity (ROE) | -0.58% |
| Return on Assets (ROA) | -0.25% |
| Return on Capital (ROIC) | -62.13% |
| Revenue Per Employee | $411,483.25 |
| Profits Per Employee | $-451,355.66 |
| Employee Count | 627 |
| Asset Turnover | 0.22 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1M |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -56.78% in the last 52 weeks. The beta is 1.36, so Arcus Biosciences's price volatility has been higher than the market average.
| Beta | 1.36 |
| 52-Week Price Change | -56.78% |
| 50-Day Moving Average | 11.13 |
| 200-Day Moving Average | 14.75 |
| Relative Strength Index (RSI) | 30.17 |
| Average Volume (20 Days) | 938.05K |
Income Statement
In the last 12 months, Arcus Biosciences had revenue of 258M and earned -283M in profits. Earnings per share was -3.14.
| Revenue | 258M |
| Gross Profit | 258M |
| Operating Income | -330M |
| Net Income | -283M |
| EBITDA | -269M |
| EBIT | -330M |
| Earnings Per Share (EPS) | -3.14 |
Balance Sheet
The company has 150M in cash and 48M in debt, giving a net cash position of 102M.
| Cash & Cash Equivalents | 150M |
| Total Debt | 48M |
| Net Cash | 102M |
| Retained Earnings | -1.13B |
| Total Assets | 1.15B |
| Working Capital | 790M |
Cash Flow
In the last 12 months, operating cash flow was -170M and capital expenditures -6M, giving a free cash flow of -176M.
| Operating Cash Flow | -170M |
| Capital Expenditures | -6M |
| Free Cash Flow | -176M |
| FCF Per Share | -1.95 |
Margins
Gross margin is 100%, with operating and profit margins of -127.91% and -109.69%.
| Gross Margin | 100% |
| Operating Margin | -127.91% |
| Pretax Margin | -109.69% |
| Profit Margin | -109.69% |
| EBITDA Margin | -104.26% |
| EBIT Margin | -127.91% |
| FCF Margin | -68.22% |
Dividends & Yields
RCUS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -38.48% |
| FCF Yield | -20.37% |
Analyst Forecast
The average price target for RCUS is $29, which is 255.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $29 |
| Price Target Difference | 255.4% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | -0.34 |
| Piotroski F-Score | 3 |